EXTENSIVE-STAGE SMALL CELL LUNG CANCER

This study tests whether adding low-dose radiation to standard chemotherapy and an immunotherapy drug can help people with extensive-stage small cell lung cancer live longer without their cancer growing. About 61 people who have not had prior treatment for this stage will receive…

This study tested a new treatment for people with extensive-stage small cell lung cancer, a fast-growing cancer that has spread. The treatment combines low-dose radiation, an immunotherapy drug (durvalumab), and standard chemotherapy. The goal was to see if this combination helps…

This study tests a new drug called BNT327 combined with chemotherapy for people with a hard-to-treat type of lung cancer (small-cell lung cancer). About 110 adults with either newly diagnosed or previously treated cancer will take part. The goal is to see if the combo shrinks tum…

This study tests a new drug, serplulimab, combined with chemotherapy, against the current standard treatment (atezolizumab plus chemo) for people with extensive-stage small cell lung cancer who have not had prior treatment. About 200 participants will be randomly assigned to one …

This study tests a new drug called tarlatamab combined with standard chemotherapy and an immunotherapy for people with extensive stage small cell lung cancer who have not had prior treatment. The main goal is to check the safety and side effects of this combination. About 184 adu…

This early-stage trial is testing whether adding a special type of radiation (adaptive SBRT) to standard immunotherapy and chemotherapy is safe for people with advanced small cell lung cancer that has stopped responding to platinum chemo. About 50 adults with this cancer will rec…

This study tests whether adding tarlatamab to durvalumab helps people with extensive-stage small-cell lung cancer live longer. About 563 adults who finished initial chemotherapy and durvalumab without their cancer getting worse will be randomly assigned to get either the combinat…

This study tests a new drug, [177Lu]Lu-DOTA-TATE, combined with standard chemotherapy and immunotherapy for people newly diagnosed with extensive stage small cell lung cancer. The goal is to find a safe dose and see if the combination helps people live longer. About 24 adults wil…

This study planned to test two drugs, tarlatamab and sacituzumab govitecan, in people with advanced small cell lung cancer or a similar neuroendocrine cancer that had not responded to prior treatment. The goal was to see if the combination was safe and could shrink tumors. Howeve…

This early-stage study aimed to test whether adding low-dose radiation to standard chemotherapy and two immunotherapy drugs (toripalimab and tifcemalimab) could be safe and tolerable for people with extensive-stage small cell lung cancer who had not been treated before. The study…

This study tests a new drug called ifinatamab deruxtecan (I-DXd) in people with advanced small cell lung cancer that has spread and has been treated before. The goal is to see if the drug can shrink tumors and find the best dose. About 187 adults will take part in this Phase 2 tr…

This study tests a drug called MGC018 in people with a hard-to-treat type of lung cancer (extensive-stage small-cell lung cancer) that has come back or not responded to prior treatment. The main goal is to see if the drug can shrink tumors in at least 25% of participants. Patient…

This study tests a drug called tarlatamab in 32 Chinese adults with advanced small cell lung cancer that has worsened after at least two prior treatments. The main goal is to see if the drug can shrink tumors. This is a Phase 2a trial, meaning it's still early, and the drug aims …

This study tests a personalized vaccine (made from each patient's unique tumor markers) combined with the immunotherapy drug durvalumab in people with extensive-stage small cell lung cancer. The goal is to see if this combination is safe and can slow cancer growth. Only 6 partici…